p50-Deficient Immature Myeloid Cells Enhance Tumor Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches, such as T cell checkpoint inhibition, are limited by suppressive tumor myeloid cells, and existing treatments using mature macrophages have shown limited efficacy due to poor tumor localization, necessitating the development of novel methods to enhance anti-tumor T cell immunity.
Innovation Solution
The development of autologous bone marrow hematopoietic progenitor cells with reduced or absent NF-κB p50 expression, which are expanded and infused as immature myeloid cells (IMC) to generate activated macrophages and dendritic cells that can effectively target tumors, potentially combined with chemotherapy and checkpoint inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mature macrophages are used for cancer immunotherapy, then anti-tumor immunity is activated, but tumor localization is poor and efficacy is limited
Solution Approach 1:
The patent applies preliminary action by using immature myeloid cells (IMCs) that are pre-programmed with migratory properties and tumor-homing capabilities before infusion. These IMCs can rapidly traverse the tumor microenvironment and deliver anti-tumor functions at the tumor site, overcoming the poor localization issue of mature macrophages while maintaining anti-tumor immunity activation.
Solution Approach 2:
The patent changes the developmental stage parameter of myeloid cells from mature to immature, which fundamentally alters their biological properties. Immature myeloid cells exhibit enhanced migratory capacity, plasticity, and ability to penetrate tumor barriers compared to mature macrophages, thereby improving tumor localization while preserving anti-tumor immune activation capabilities.
2Reliability
If T cell checkpoint inhibition is used for cancer therapy, then anti-tumor T cell immunity is enhanced, but T cell-suppressive tumor myeloid cells limit effectiveness
Solution Approach 1:
The patent converts the harmful effect of tumor myeloid cells into a benefit by using immature myeloid cells as therapeutic agents. These IMCs can infiltrate the tumor microenvironment, suppress T cell suppression mechanisms, and enhance anti-tumor T cell immunity, thereby transforming the previously harmful myeloid cell population into a beneficial therapeutic component that synergizes with checkpoint inhibition.
Solution Approach 2:
The patent introduces immature myeloid cells as an intermediary between T cell checkpoint inhibition and anti-tumor immunity enhancement. These IMCs mediate the synergistic effect by suppressing T cell suppressive mechanisms and enhancing T cell activation, thereby amplifying the overall anti-tumor response when combined with checkpoint inhibitors.
3Ease of manufacture
If p50-deficient immature myeloid cells are infused, then tumor localization is improved, but cell generation and manipulation complexity increases
Solution Approach 1:
The patent uses p50-deficient mouse models as a natural copy or template for generating human p50-deficient immature myeloid cells. By utilizing the genetic background of p50-/- mice, the complex manipulation of p50 deficiency can be achieved through model organism research and translation, simplifying the overall process of generating and characterizing human therapeutic IMCs with similar properties.
Data Source
AI summary
The present invention provides methods for making autologous bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit (p50). The progenitor cells are expanded, exposed to a myeloid cytokine, and provided intravenously to treat various malignancies. The infused cells have the potential to generate mature granulocytes, monocytes, macrophages, and dendritic cells that are activated due to the absence of p50. Methods for the genetically manipulation of a subject's hematopoietic progenitors during the expansion phase to reduce or eliminate p50 expression are also contemplated, and these progenitor cells may be combined with other therapeutic agents to maximize efficacy.